This company creates and commercialises products that lower healthcare costs and improve health outcomes. They develop these products themselves or through partnerships to enhance outpatient care for specific acute conditions. Their main product in development, FUROSCIX, involves a formulation of furosemide delivered through a wearable device for the treatment of edema in adults with conditions like congestive heart failure, liver cirrhosis and renal disease. Other products in their pipeline include scCeftriaxone and scCarbapenem, both antibiotics for intravenous use in treating infections caused by certain bacteria.